Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 506 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed... May 19, 2021 Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... March 14, 2022 The American Rescue Act: What You Need to Know March 16, 2021 England moves to a single-dose HPV vaccine June 21, 2023 Load more HOT NEWS FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer Spotlight On: Exercise Physiologists in Cancer Care Cancer in My Community: Overcoming Inequities in Care in Argentina Researchers Discover New Way to Prevent Hair Loss During Chemotherapy Treatment
